regeneron q4 - Search News

Q4 Earnings Snapshot

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2024 Earnings Call Transcript

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter 2024 Earnings Conference Call. My name is Tawanda, and I will be your operator for today’s call.

SFGate · 1d

Regeneron: Q4 Earnings Snapshot

On a per-share basis, the Tarrytown, New York-based company said it had profit of $8.06. Earnings, adjusted for stock option expense and non-recurring costs, were $12.07 per share. The results beat Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $11.62 per share.

The Washington Post · 6h

Banco Santander: Q4 Earnings Snapshot

Banco Santander SA (SAN) on Wednesday reported net income of $3.48 billion in its fourth quarter. The bank, based in Madrid, said it had earnings of 21 cents per share. The financial holding company posted revenue of $17.

Regeneron Presents An Opportunity After LIBTAYO Sales Growth Bolsters Earnings

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

StockStory.org on MSN1d

Regeneron’s (NASDAQ:REGN) Q4 Sales Top Estimates, Stock Soars

Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results , with sales up 10.3% year on year to $3.79 billion. Its ...

Regeneron reports Q4 non-GAAP EPS $12.07, consensus $11.19

Reports Q4 revenue $3.79B, consensus $3.75B. “Regeneron’s (REGN) financial and commercial strength allows for continued investment in our ...

22h

Regeneron Q4 Earnings: Dividend And Dupixent Drive Solid Quarter - Eylea To Strike Back In 2025

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Regeneron Pharma Q4 Earnings Crush Estimates, Initiates Dividend And Additional Stock Buyback Program

Regeneron beat Q4 estimates with $12.07 EPS and $3.79B in sales. The company announced a dividend, a $3 billion buyback, and continued R&D investments.

Regeneron Pharmaceuticals Q4 Profit Decreases, But Beats Estimates

Regeneron Pharmaceuticals (REGN) announced earnings for fourth quarter that decreased from the same period last year but beat the ...

Regeneron 4Q Rev Up on Strong Sales of EYLEA HD

Revenue rose 10% to $3.79 billion, surpassing the average $3.74 billion target from analysts polled by FactSet. Sales of the EYLEA HD more than doubled to $305 million. The medication was approved for ...

Yahoo Finance4d

Ahead of Regeneron (REGN) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics

The upcoming report from Regeneron (REGN) is expected to reveal quarterly earnings of $11.60 per share, indicating a decline of 2.2% compared to the year-ago period. Analysts forecast revenues of ...

Regeneron price target raised to $575 from $565 at BofA

BofA raised the firm’s price target on Regeneron (REGN) to $575 from $565 and keeps an Underperform rating on the shares. Q4 results were ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results